Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vancomycin | 8 | 2016 | 38 | 2.490 |
Why?
|
| Anti-Bacterial Agents | 8 | 2018 | 785 | 2.110 |
Why?
|
| Drug Prescriptions | 3 | 2018 | 168 | 1.260 |
Why?
|
| Hospitals, Pediatric | 5 | 2017 | 50 | 1.160 |
Why?
|
| Antimicrobial Stewardship | 2 | 2018 | 16 | 1.150 |
Why?
|
| Anti-Infective Agents | 3 | 2017 | 149 | 1.090 |
Why?
|
| Child | 19 | 2021 | 4436 | 1.080 |
Why?
|
| Child, Preschool | 14 | 2021 | 1932 | 0.940 |
Why?
|
| Fluoroquinolones | 2 | 2015 | 34 | 0.920 |
Why?
|
| Drug Utilization Review | 2 | 2016 | 52 | 0.860 |
Why?
|
| Infant | 13 | 2025 | 1594 | 0.860 |
Why?
|
| Medical Audit | 3 | 2017 | 60 | 0.800 |
Why?
|
| Child, Hospitalized | 3 | 2016 | 16 | 0.730 |
Why?
|
| Drug Utilization | 2 | 2013 | 210 | 0.690 |
Why?
|
| Enteral Nutrition | 1 | 2021 | 54 | 0.690 |
Why?
|
| Appendicitis | 2 | 2018 | 81 | 0.670 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2015 | 203 | 0.660 |
Why?
|
| Minority Groups | 1 | 2021 | 139 | 0.640 |
Why?
|
| Clostridium Infections | 1 | 2019 | 49 | 0.600 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2014 | 23 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 445 | 0.580 |
Why?
|
| Peritonitis | 1 | 2018 | 36 | 0.580 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2015 | 90 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 725 | 0.550 |
Why?
|
| Sepsis | 1 | 2021 | 279 | 0.540 |
Why?
|
| Surgical Wound Infection | 3 | 2018 | 112 | 0.540 |
Why?
|
| Cross Infection | 2 | 2015 | 160 | 0.530 |
Why?
|
| Colletotrichum | 1 | 2016 | 1 | 0.520 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 348 | 0.510 |
Why?
|
| Dermatomycoses | 1 | 2016 | 14 | 0.510 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 316 | 0.490 |
Why?
|
| Candidemia | 1 | 2015 | 9 | 0.480 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 20 | 0.480 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 107 | 0.480 |
Why?
|
| Male | 22 | 2025 | 29472 | 0.470 |
Why?
|
| Candida | 1 | 2015 | 38 | 0.470 |
Why?
|
| Rhizopus | 1 | 2014 | 5 | 0.460 |
Why?
|
| Mucormycosis | 1 | 2014 | 10 | 0.460 |
Why?
|
| Amphotericin B | 1 | 2014 | 23 | 0.460 |
Why?
|
| Photosensitivity Disorders | 1 | 2014 | 1 | 0.460 |
Why?
|
| Porphyrias | 1 | 2014 | 2 | 0.460 |
Why?
|
| Adolescent | 10 | 2021 | 6165 | 0.460 |
Why?
|
| Voriconazole | 1 | 2014 | 6 | 0.460 |
Why?
|
| Onycholysis | 1 | 2014 | 2 | 0.460 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 6 | 0.460 |
Why?
|
| Escherichia coli Infections | 1 | 2015 | 87 | 0.450 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 49 | 0.450 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 90 | 0.440 |
Why?
|
| Aspergillosis | 1 | 2014 | 40 | 0.440 |
Why?
|
| Humans | 30 | 2025 | 62653 | 0.440 |
Why?
|
| Medical Order Entry Systems | 2 | 2017 | 42 | 0.430 |
Why?
|
| Meningitis, Fungal | 1 | 2013 | 2 | 0.430 |
Why?
|
| Histoplasma | 1 | 2013 | 16 | 0.420 |
Why?
|
| Histoplasmosis | 1 | 2013 | 24 | 0.420 |
Why?
|
| Skin | 1 | 2016 | 377 | 0.410 |
Why?
|
| Orthopedic Procedures | 1 | 2012 | 47 | 0.390 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 177 | 0.380 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 189 | 0.380 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 129 | 0.380 |
Why?
|
| Infant, Newborn | 8 | 2025 | 1338 | 0.370 |
Why?
|
| Female | 20 | 2025 | 32478 | 0.360 |
Why?
|
| Escherichia coli | 1 | 2015 | 708 | 0.340 |
Why?
|
| Young Adult | 7 | 2021 | 4633 | 0.330 |
Why?
|
| Hospitals, Teaching | 3 | 2016 | 104 | 0.320 |
Why?
|
| Medication Systems, Hospital | 1 | 2009 | 9 | 0.310 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2009 | 9 | 0.310 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 660 | 0.310 |
Why?
|
| Chagas Disease | 2 | 1999 | 35 | 0.310 |
Why?
|
| Antibodies, Protozoan | 2 | 1999 | 52 | 0.310 |
Why?
|
| Trypanosoma cruzi | 2 | 1999 | 51 | 0.310 |
Why?
|
| Bacterial Infections | 1 | 2010 | 148 | 0.310 |
Why?
|
| Body Mass Index | 1 | 2012 | 864 | 0.300 |
Why?
|
| Neoplasms | 1 | 2019 | 1350 | 0.300 |
Why?
|
| Retrospective Studies | 6 | 2025 | 6528 | 0.300 |
Why?
|
| Medication Errors | 1 | 2009 | 108 | 0.290 |
Why?
|
| Prospective Studies | 4 | 2017 | 3258 | 0.280 |
Why?
|
| Smallpox | 1 | 2006 | 9 | 0.250 |
Why?
|
| Smallpox Vaccine | 1 | 2006 | 14 | 0.250 |
Why?
|
| Parechovirus | 1 | 2025 | 1 | 0.250 |
Why?
|
| Picornaviridae Infections | 1 | 2025 | 3 | 0.250 |
Why?
|
| Meningoencephalitis | 1 | 2025 | 8 | 0.250 |
Why?
|
| Ilex paraguariensis | 1 | 2005 | 1 | 0.240 |
Why?
|
| Levofloxacin | 2 | 2015 | 13 | 0.230 |
Why?
|
| Food Microbiology | 1 | 2005 | 43 | 0.230 |
Why?
|
| Recurrence | 2 | 2019 | 634 | 0.230 |
Why?
|
| Lung Abscess | 1 | 2004 | 6 | 0.230 |
Why?
|
| Fungi | 1 | 2005 | 57 | 0.230 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2004 | 8 | 0.230 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2004 | 16 | 0.230 |
Why?
|
| Beverages | 1 | 2005 | 67 | 0.230 |
Why?
|
| Delaware | 2 | 2015 | 6 | 0.220 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2004 | 37 | 0.220 |
Why?
|
| Infant, Premature, Diseases | 1 | 2004 | 47 | 0.220 |
Why?
|
| Clindamycin | 2 | 2014 | 13 | 0.220 |
Why?
|
| Risk Factors | 3 | 2021 | 5302 | 0.210 |
Why?
|
| Bacteremia | 1 | 2004 | 94 | 0.210 |
Why?
|
| Pediatrics | 1 | 2006 | 249 | 0.210 |
Why?
|
| Hospitalization | 3 | 2019 | 1344 | 0.210 |
Why?
|
| Tennessee | 2 | 2018 | 16 | 0.180 |
Why?
|
| Leuconostoc | 1 | 2021 | 1 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 453 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 44 | 0.180 |
Why?
|
| Clinical Competence | 1 | 2006 | 713 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2018 | 5587 | 0.170 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 1999 | 6 | 0.160 |
Why?
|
| Prognosis | 2 | 2025 | 1724 | 0.160 |
Why?
|
| Incidence | 2 | 2021 | 1367 | 0.150 |
Why?
|
| United States | 3 | 2021 | 7718 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 370 | 0.150 |
Why?
|
| Flavobacterium | 1 | 1998 | 1 | 0.150 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 775 | 0.150 |
Why?
|
| Meningitis, Bacterial | 1 | 1998 | 6 | 0.150 |
Why?
|
| Rifampin | 1 | 1998 | 25 | 0.150 |
Why?
|
| Immunoglobulin A | 1 | 1999 | 97 | 0.150 |
Why?
|
| Sex Factors | 1 | 2021 | 972 | 0.140 |
Why?
|
| Feedback | 1 | 2017 | 89 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 65 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 46 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 463 | 0.130 |
Why?
|
| Age Factors | 1 | 2021 | 1554 | 0.130 |
Why?
|
| Appendectomy | 1 | 2016 | 54 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2016 | 52 | 0.120 |
Why?
|
| Ciprofloxacin | 1 | 2015 | 25 | 0.120 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 31 | 0.120 |
Why?
|
| Pennsylvania | 1 | 2015 | 64 | 0.120 |
Why?
|
| Administration, Topical | 1 | 2014 | 52 | 0.110 |
Why?
|
| Echinocandins | 1 | 2014 | 3 | 0.110 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2014 | 2 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 109 | 0.110 |
Why?
|
| Cheilitis | 1 | 2014 | 5 | 0.110 |
Why?
|
| Magnesium Deficiency | 1 | 2014 | 3 | 0.110 |
Why?
|
| Lipopeptides | 1 | 2014 | 15 | 0.110 |
Why?
|
| Cephalosporins | 1 | 2014 | 18 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 94 | 0.110 |
Why?
|
| Hypokalemia | 1 | 2014 | 13 | 0.110 |
Why?
|
| Biopsy | 1 | 2016 | 429 | 0.110 |
Why?
|
| Blister | 1 | 2014 | 17 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2014 | 122 | 0.110 |
Why?
|
| Ankle | 1 | 2014 | 28 | 0.110 |
Why?
|
| Substantia Nigra | 1 | 2014 | 14 | 0.110 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 57 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2014 | 15 | 0.110 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 42 | 0.110 |
Why?
|
| Cicatrix | 1 | 2014 | 61 | 0.110 |
Why?
|
| Creatine | 1 | 2013 | 24 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2014 | 126 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 60 | 0.110 |
Why?
|
| Encephalitis | 1 | 2014 | 34 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 306 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2445 | 0.110 |
Why?
|
| Corpus Striatum | 1 | 2014 | 96 | 0.100 |
Why?
|
| Cefazolin | 1 | 2012 | 9 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 156 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 54 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 707 | 0.100 |
Why?
|
| Body Weight | 1 | 2013 | 377 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2012 | 85 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 608 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 535 | 0.090 |
Why?
|
| Microglia | 1 | 2014 | 238 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 2149 | 0.090 |
Why?
|
| Organizational Policy | 1 | 2010 | 48 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 748 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1108 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2021 | 2537 | 0.080 |
Why?
|
| Logistic Models | 1 | 2012 | 1273 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1638 | 0.080 |
Why?
|
| Neurons | 1 | 2014 | 909 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2010 | 355 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2010 | 852 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2009 | 485 | 0.070 |
Why?
|
| Chickenpox | 1 | 2006 | 3 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2006 | 2540 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2025 | 114 | 0.060 |
Why?
|
| Electroencephalography | 1 | 2025 | 147 | 0.060 |
Why?
|
| Mycobacterium chelonae | 1 | 2004 | 1 | 0.060 |
Why?
|
| Brain | 1 | 2013 | 1550 | 0.060 |
Why?
|
| Data Collection | 1 | 2006 | 384 | 0.060 |
Why?
|
| Vaccination | 1 | 2006 | 352 | 0.050 |
Why?
|
| Pregnancy | 2 | 1999 | 2315 | 0.050 |
Why?
|
| Adult | 2 | 2013 | 16623 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 258 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 1540 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 1999 | 49 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1999 | 76 | 0.040 |
Why?
|
| Gestational Age | 1 | 1999 | 188 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1998 | 142 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2646 | 0.040 |
Why?
|
| Time Factors | 1 | 2004 | 3740 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 67 | 0.030 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2016 | 28 | 0.030 |
Why?
|
| Catheterization, Peripheral | 1 | 2016 | 53 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 497 | 0.030 |
Why?
|
| Animals | 3 | 2014 | 20579 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 290 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 47 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 95 | 0.030 |
Why?
|
| Neural Pathways | 1 | 2014 | 98 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 334 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 804 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2016 | 429 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 422 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 773 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 1586 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1528 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1184 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3387 | 0.020 |
Why?
|
| Mice | 1 | 2014 | 10802 | 0.010 |
Why?
|